Viventia Biotech Inc.

Viventia Biotech Inc. is a leader in developing innovative therapeutics based upon the human immune response to cancer. Through its Hybridomics™ discovery platform and ImmunoMine™ screening technology, the Company is focused on developing "Totally Human" monoclonal antibodies either as targeted therapeutics, Armed Antibodies™, or as direct treatments to fight multiple forms of cancer.

Contact Details: 147 Hamelin Street Winnipeg Manitoba R3T 3Z1 Canada Tel: 204 478 1023 Fax: 204 452 7721 Email: hr@viventia.com WWW: www.viventia.com/

Loading...

Recent Publications by Viventia Biotech Inc.:
A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. VB4-845 is a novel recombinant fusion protein that targets the epithelial...	19th November, 2008	Viventia Biotech Inc., 147 Hamelin St., Winnipeg, MB, Canada R3T 3Z1.	Med Oncol. 2009;26(3):257-64. Epub 2008 Oct 28. DOI Direct Link
A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab PF-2D in tandem with mass spectrometry. Mapping differential expression of soluble proteins has become fairly...	25th October, 2006	Viventia Biotech Inc., 147 Hamelin street, Winnipeg, MB, Canada R3T3Z1.	Biochem Biophys Res Commun. 2006 Sep 29;348(3):1055-62. Epub 2006 Aug 7. DOI Direct Link
Effective tumor targeting: strategies for the delivery of Armed Antibodies. It has long been realized that the presence of tumor-associated antigens...	14th June, 2005	Viventia Biotech Inc, 147 Hamelin Street, Winnipeg, Manitoba R3T 3Z1,	Curr Opin Drug Discov Devel. 2005 Mar;8(2):177-83.

BioNews Results for Viventia Biotech Inc.:
Updates for SunLink (NYSE:SSY), Enzo Biochem Inc. (NYSE:ENZ), Pro-Pharmaceuticals (OTC:PRWP)	American Chronicle:  Nov 16 2009 12:50AM Matching: biotech inc
Updates for Oculus (NASDAQ:OCLS), Orthovita (NASDAQ:VITA), Ore Pharmaceutical (NASDAQ:ORXE)	American Chronicle:  Nov 16 2009 12:50AM Matching: biotech inc
Tiens Biotech Group USA Inc. (TBV) Corporate Event Announcement N...	Zibb:  Nov 15 2009 3:06AM Matching: biotech inc
Maxygen Buying Back Stock; Analysts Say No Trend Here	BioWorld:  Nov 14 2009 6:06AM Matching: biotech inc
Hungry for biotech deals	Reuters:  Nov 14 2009 6:03AM Matching: biotech inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Viventia Biotech Inc. news.

Viventia Biotech Inc. Patents:
US Patent No.	Title
7166286	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
7115722	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
6420551	Antisense oligonucleotides targeted against human immunodeficiency virus
6355444	Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and uses therefor
6207153	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
→View more Viventia Biotech Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 397 times since April 2007, the link to the organisation's website has been followed 83 times

Search for more companies in Winnipeg

Search for more companies in Manitoba

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Viventia Biotech Inc.